Publications by authors named "M Pradier"
Introduction: Outpatient management of pulmonary embolism (PE) remains controversial in patients with cancer due to their higher risks of mortality, recurrent venous thromboembolism (VTE) and bleeding complications. This systematic review and meta-analysis aimed to evaluate the safety and feasibility of outpatient management of cancer-associated PE.
Methods: We searched MEDLINE, Embase, Cochrane Central, and Scopus databases from inception to May 30, 2024, for studies on outpatient management of cancer-associated PE.
Introduction: Total nephrectomies for the treatment of Wilms' tumor (WT) are more and more performed by laparoscopy, although indications for this approach following the UMBRELLA guidelines are currently very restrictive. The purpose of this study was to assess the compliance to the criteria of the UMBRELLA protocol for minimally invasive approach of WT.
Methods: This retrospective multicenter study included children operated on by laparoscopic total nephrectomy for suspected WT before 2020.
Article Synopsis
- - The study investigates the shift to virtual care for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) during the COVID-19 pandemic at the Ottawa Hospital Cancer Center from June 2019 to December 2022.
- - Out of 103 patients, a significant portion of follow-up visits (76.1%) and some consultations (17.5%) were conducted virtually, with a gradual return to in-person visits by 2022.
- - The findings indicate that virtual care played a major role in managing GEP-NET patients during the pandemic and suggests that it may enhance access to specialized care in the future.
Objectives: We aimed to describe the efficacy and safety of dalbavancin in treatment of patients with diabetes-related foot osteomyelitis with bone culture confirmation.
Patients And Methods: Between January 2019 and December 2021, all consecutive patients receiving at least one 1500 mg dose of dalbavancin for diabetes-related foot osteomyelitis were included in a retrospective study. Remission was defined as absence of relapsing infection or need for surgery at the initial or a contiguous site during 6-month follow-up from the last dose of dalbavancin.